口服抗癌药的药代动力学药物相互作用潜力
研究汇编了口服抗癌药(OAD)的临床相关药代动力学(PK)药物相互作用(DDI)机制,并回顾性分析了3,697例晚期实体瘤患者的电子健康记录以评估潜在PK DDI(PDDI)的患病率。结果显示85.9%的OAD具有至少一种DDI机制,46.9%的患者被处方至少一种OAD,其中17.4%存在至少一种PDDI。
要点
- 85.9%的口服抗癌药具有至少一种DDI机制。
- 46.9%的实体瘤患者被处方至少一种口服抗癌药。
- 17.4%使用口服抗癌药的患者存在至少一种潜在PK DDI。
核心结论
- 大多数口服抗癌药(约86%)具有至少一种DDI机制,约17%的实体瘤患者存在临床相关的潜在PK DDI。
研究设计与样本
- 回顾性研究,审查了3,697例晚期实体瘤患者的电子健康记录以检测潜在PK DDI。
- 从药品说明书和原始文献中提取OAD的DDI机制,共分析748对药物-药物组合。
主要发现
- 85种OAD(85.9%)具有至少一种DDI机制。
- 最常见的DDI机制为代谢诱导剂受害者(71.7%)、CYP3A底物(55.6%)、CYP3A肇事者(29.3%)和酸抑制剂受害者(17.2%)。
- 原始文献检索发现14种药物具有临床相关DDI机制但药品说明书无可行建议。
- 在处方至少一种OAD的患者(46.9%)中,17.4%存在至少一种PDDI,最常见涉及OAD作为CYP3A(58.9%)或CYP2D6(32.5%)肇事者。
关键数值与推荐
- DDI机制定义基于与相互作用药物合用时暴露变化≥2倍或显著不良健康结局的研究。
- PDDI定义为OAD与相关相互作用药物的重叠处方。
临床怎么用
- 临床应关注口服抗癌药与代谢诱导剂、CYP3A底物/肇事者、酸抑制剂等的相互作用。
- 对使用OAD的患者应筛查潜在PK DDI,尤其是CYP3A和CYP2D6介导的相互作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Drug-drug interaction (DDI) management is critical for safe and effective use of oral anticancer drugs (OADs). Our study objectives were to (i) compile clinically relevant pharmacokinetic (PK) DDI mechanisms for OADs and (ii) assess the prevalence of PK potential DDIs (PDDIs) in patients with advanced solid cancers. OADs approved through January 2023 were assigned DDI mechanisms based on studies obtained from drug labels and primary literature showing ≥ 2-fold exposure change or significant adverse health outcomes during co-administration with interacting drugs. Electronic health records of 3,697 solid cancer patients were reviewed retrospectively to detect PDDIs, defined as overlapping prescriptions of OADs with relevant interacting drugs. FDA labels were reviewed for 99 OADs, and 239 studies were extracted from the primary literature, yielding a total of 748 drug-drug pairs for analysis. Eighty-five OADs (85.9%) had ≥ 1 DDI mechanism. The most common DDI mechanisms were victims with metabolic inducers (71.7%), CYP3A substrates (55.6%), CYP3A perpetrators (29.3%), and victims with acid reducers (17.2%). Our primary literature search detected clinically relevant DDI mechanisms without actionable recommendations in the drug labels for 14 drugs. Among patients prescribed ≥ 1 OADs (46.9%), 17.4% had ≥ 1 PDDI, most commonly involving OADs acting as CYP3A (58.9%) or CYP2D6 (32.5%) perpetrators. Most OADs (~86%) had ≥ 1 DDI mechanism, and ~17% of solid tumor board patients had a clinically relevant PDDI.
引用
- Alhurayri F, Younis IR, Jalal SI, et al. Pharmacokinetic Drug-Drug Interaction Potential of Oral Anticancer Drugs. Clin Pharmacol Ther. 2026. PMID: 41793262. doi:10.1002/cpt.70253
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。